Study Summary
This trial is testing a new transcatheter mitral valve replacement system to see if it is safe and effective in treating patients with severe mitral regurgitation who are not candidates for open heart surgery.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: 30 days post implant
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Treatment
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Cephea Mitral Valve System · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many test centers are actively conducting this experiment?
"11 medical centres are currently enrolling participants for this trial, including Montefiore Medical Centre in Bronx, The Cleveland Clinic Foundation in Cleveland and The Methodist Hospital in Houston. Additionally, there are 8 other sites providing access to the treatment." - Anonymous Online Contributor
Are there vacancies to enroll in this clinical research endeavor?
"Affirmative. The information available on clinicaltrials.gov attests to this medical trial's active recruitment status, which commenced at the end of April 2022 and was recently modified in late August 2022. This study requires 30 individuals across 11 different sites for its completion." - Anonymous Online Contributor
How many subjects are being monitored for this clinical experiment?
"Affirmative, the information on clinicaltrials.gov suggests that this experiment is presently recruiting patients. It was posted on April 28th of 2022 and updated most recently on August 23rd; 30 people are needed across 11 sites for enrollment." - Anonymous Online Contributor